PNAS, Edited by Philip C. Hanawalt, Stanford University, Stanford, CA, and approved November 27, 2009 (received for review August 26, 2009)
Yunfu Lina, Sharon Y. R. Dentb, John H. Wilsona, Robert D. Wellsc, and Marek Napieralab,c,1
aBaylor College of Medicine, Verna and Marrs McLean Department of Biochemistry and Molecular Biology, One Baylor Plaza, Houston, TX 77030;
bUniversity of Texas M. D. Anderson Cancer Center, Department of Biochemistry and Molecular Biology and Center for Cancer Epigenetics, 1515 Holcombe Boulevard, Houston, TX 77030; and
cCenter for Genome Research, Institute of Biosciences and Technology, Texas A&M Health Science Center, 2121 West Holcombe Boulevard, Houston, TX 77030.
This article contains supporting information online at www.pnas.org/cgi/content/full/0909740107/DCSupplemental.
Tuesday, February 16, 2010
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases
Expert Opinion on Drug Safety. Posted online on 09 Jan 2010.
G J Kontoghiorghes†1, A Kolnagou2, C-T Peng3, S V Shah4 & A Aessopos5
1Postgraduate Research Institute of Science, Technology, Environment and Medicine, 3 Ammochostou Sreet, Limassol, 3021. Cyprus+35 7 2627 2076; +35 72 627 1434; kontoghiorghes.g.j@pri.ac.cy
2Postgraduate Research Institute, Science, Technology, Environment and Medicine Limassol and Thalassaemia unit, Paphos General Hospital, Paphos, Cyprus
3Children's Medical Center, China Medical University Hospital, Taichung, Taiwan
4Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, USA
5First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece
Keywords: thalassaemia, chelation therapy, body iron levels, neurodegenerative, renal, infectious diseases, chelator overdose toxicity, essential metal deficiencies, deferoxamine, deferasirox, deferiprone, short-term treatments, longer term treatments, non-iron loading conditions.
G J Kontoghiorghes†1, A Kolnagou2, C-T Peng3, S V Shah4 & A Aessopos5
1Postgraduate Research Institute of Science, Technology, Environment and Medicine, 3 Ammochostou Sreet, Limassol, 3021. Cyprus+35 7 2627 2076; +35 72 627 1434; kontoghiorghes.g.j@pri.ac.cy
2Postgraduate Research Institute, Science, Technology, Environment and Medicine Limassol and Thalassaemia unit, Paphos General Hospital, Paphos, Cyprus
3Children's Medical Center, China Medical University Hospital, Taichung, Taiwan
4Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, USA
5First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece
Keywords: thalassaemia, chelation therapy, body iron levels, neurodegenerative, renal, infectious diseases, chelator overdose toxicity, essential metal deficiencies, deferoxamine, deferasirox, deferiprone, short-term treatments, longer term treatments, non-iron loading conditions.
Subscribe to:
Posts (Atom)
